Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 26s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Study Of Tableting Properties of C12, C14, C16, C18 Saturated Fatty Acid Derivatives of Starch Soluble

Naveen Khatri*[1], Sandeep Jain[2], Neelam Jain[3]

[1*]College of Pharmacy, Pt. BD Sharma, University of Health Sciences, Rohtak, Haryana, India.

[2]Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science & Technology, Hisar, Haryana, India.

[3]Department of Pharmaceutical Education and Research, BPS Mahila Vishwavidyalaya, Khanpur Kalan, Sonipat, Haryana, India,

***Correspondence Author:**

Naveen Khatri,

[1*]College of Pharmacy, Pt. BD Sharma, University of Health Sciences, Rohtak, Haryana, India.

Email ID: brijeshkumarsaroj9@gmail.com

Cite this paper as: Naveen Khatri, Sandeep Jain, Neelam Jain, (2025) Study Of Tableting Properties of C12, C14, C16, C18 Saturated Fatty Acid Derivatives of Starch Soluble, *Journal of Neonatal Surgery*, 14 (26s), 952-960

ABSTRACT

Pharmaceutical excipients are needed in a formulation as diluents, binders, and other constituents. One of the most employed excipients in the pharmaceutical industry is starch, which has both the binding and disintegrating capabilities. This study assesses starch long-chain saturated fatty acid derivatives (C12- C18) for their weight, physical, excipient, and tableting features. The results argume that fat acid esterification results in hydrophobicity which facilitates sustained the drug release. Starch laurate (C12) demonstrated (23.6 cps) and (angle of repose: 30.73°) the greatest viscostiy and flowability, respectively; while starch stearate (C18) had the slowest drug release rate. These suggest to the premise that modified starches with fatty acids are good candidate excipients for sustained release formulation.

1. INTRODUCTION

Starch, a naturally abundant polysaccharide composed of amylose (linear α-1,4-glucan) and amylopectin (branched α-1,4- and α-1,6-glucan), serves as a fundamental excipient in pharmaceutical formulations. Its widespread use stems from three key attributes: (1) cost-effectiveness as a natural polymer [1], (2) chemical inertness ensuring formulation compatibility [2], and (3) multifunctionality as disintegrant, binder, diluent, and glidant [3,4]. The polyhydroxy structure of starch facilitates these roles through hydrogen bonding capacity and controlled swelling behavior in aqueous environments [5,6].

Rational Design of Fatty Acid-Modified Starches:

The esterification of starch with C12-C18 saturated fatty acids represents a strategic approach to enhance functionality, particularly for controlled-release applications [7]. This study specifically selected lauric (C12), myristic (C14), palmitic (C16), and stearic (C18) acids based on three critical pharmaceutical considerations:

1. ***Chain Length-Dependent Performance:***

- Progressive increase in hydrophobicity (C12 to C18) enables systematic modulation of drug release kinetics [8]
- Each fatty acid demonstrates distinct melting points and solubility profiles that influence tablet disintegration and dissolution [9]

2. ***Proven Excipient Functionality:***

    - Established lubricant properties reduce tablet ejection forces [10]
    - Binding capacity enhances mechanical strength of compressed formulations [11].
    - Native starch compatibility through efficient esterification of hydroxyl groups [12]

3. **Formulation Advantages:**

1) C12 (laurate): Optimal balance between hydrophobicity and processability [13]
2) C18 (stearate): Maximum sustained-release potential [14]

3) Intermediate chains (C14-C16): Gradient of properties for release tuning [15]

Recent advances in starch esterification [16,17] have demonstrated particular promise for hydrophobic drug delivery systems, though comparative studies across the C12-C18 series remain limited [18]. This investigation addresses this gap through comprehensive evaluation of starch fatty acid esters using cinnarizine, a BCS Class II antihistamine, as a model hydrophobic active pharmaceutical ingredient [19]. The study design enables direct comparison of key tableting parameters (compressibility, disintegration, dissolution) as a function of fatty acid chain length while maintaining consistent processing conditions [20]

2. MATERIALS AND METHOD

2.1. Materials: Palmitic acid, Myristic acid, Lauric acid, Starch soluble, Sodium Lauryl Sulphate, Talc and Magnesium Stearate were purchased from CDH. Thionyl chloride, Pyridine, Benzene, Methanol and Ethanol were purchased from Qualigens. Oxalic acid from Spectrochem, Hydrochloric acid and Sulphuric acid from Glaxo, Sodium chloride from Himedia, Potassium carbonate, Silica gel, Choloroform, Carbon tetrachloride and Dimethyl Sulphoxide from s.d. Fine Chem were procured.

2.2. Instruments: Double-Beam spectrophotometer (Perkin Elmer EZ-301, Switzerland), FTIR-Spectrophotometer (Shimadzu FTIR 8000 series, Japan), NMR (Jeol JNM FX-100 FTNMR Spectrometer), Mechanical stirrer (Universal Motors), Vortex shaker (Spinix), Weighing Balance, (AND HR 200, Japan), Water bath (Narang Scientific Works), Vacuum Dryer (Perfit India), Melting point Apparatus (Tempo), Hot Air Oven (Narang Scientific Works), Tablet disintegration test apparatus (Campbell electronics, Mumbai), Tablet Friability test apparatus (Remi equipments), Screw Gauge (Techno quality Science Instruments), Monsanto hardness tester (Macro Scientific Works), Strike-102: Rotary Evaporator (Steroglass), DV-E Viscometer (Brookfield), Digital pH meter (Century India).

2.3. Method: Long chain fatty acids i.e. Lauric acid ($CH_3(CH_2)_{10}COOH$), Myristic Acid ($CH_3(CH_2)_{12}COOH$), Palmitic Acid ($CH_3(CH_2)_{14}COOH$) and Stearic Acid ($CH_3(CH_2)_{16}COOH$) esterified corn starch esters namely starch laurate, starch myristate, starch palmitate and starch stearate were dried in rotary evaporator and powdered. This esterified starch soluble powder was further evaluated for its powder properties as in any pharmaceutical formulation raw material should be in powder form. For all the procedures starch and their derivatives were passed through sieve no. 80 to ensure particle size of 177 micrometers or less.

2.4. Powder Properties:

Viscosity Studies. Viscosity plays an important role in formulation and analytical studies of pharmaceutical products e.g. emulsion, pastes, suppositories and tablet coatings. The rheology of a particular product, which can range in consistency from fluid to semisolid to solid, can affect its formulation and patient acceptability [21]. Viscosity of starch and their derivatives was determined using Brookfield DV-E viscometer. For this 2% dispersion of powder in distilled water was made. 500 ml. solution was made (10g/500ml.) Viscosity measurements were done at room temperature (33 ± 0.5^0C) using spindle no.2 at 100 rpm and recorded in table 1.

Swelling capacity. Swelling capacity of a compound is an important criterion in determining its suspending property. For determining the swelling capacity of starch and its esters the I.P. method suggested for bentonites was followed [22]. Starch and starch esters (10.0g) were added in divided portion to distill water (100.0 ml) contained in separate measuring cylinders. Each portion was added after previous portion had traversed down. After 24 hrs swelling capacity was determined by measuring the volume of the swollen material and recorded in table 1. Swelling capacity could not be determined for starch derivatives due to floating in water. This limitation will be addressed in future studies using non-aqueous solvents.

Swelling capacity = Volume of powder at 24 hr/ Volume of powder at 0 hr

Angle of Repose. The angle of repose, Φ is used to measure the frictional forces in a loosely packed powder. Its value increases with roughness and irregular surface. With increasing departure from the spherical, the angle of repose increases while bulk density and flowability decreases [23]. It was determined by passing 50g powder through a funnel on a plain surface. Height and diameter of pile of powder were measured and this procedure was repeat 3 times and average dimensions were taken. It was calculated using following formula and recorded in table 1.

$\tan \Phi$ = Height of pile/ Radius of pile and $\Phi = \tan^{-1}$ Height of pile/ Radius of pile

pH. pH of excipient affects the release of drug from tablet and other formulations. So, compatibility of excipient with regard to pH must be tested. Ideal excipient should have pH near 7. pH of 2% dispersion was measured using Digital pH meter. 2% dispersion was made by dissolving 2g powder in distilled water up to 100ml. Readings were taken at room temperature (33^0C) and pH was recorded in table 1.

Bulk density. The tendency of the particles to adhere to one another along with particle size distribution and particle shape determines bulk density of a powder [24]. Bulk density was determined by taking 20g powder in 100ml measuring surrender. The cylinder was dropped at 2-second intervals onto a hard wood surface three times from a height of 1 inch. The bulk

density was then obtained by dividing the weight of the sample in grams by the final volume in cm^3 of the sample contained in the cylinder and bulk density is recorded in table 1.

Bulk density = Final volume/mass of powder

2.5. Formulation of tablets: Tablet remains most acceptable dosage form because of simplicity and economy of preparation, accuracy of dose, compactness, blandness to taste and ease of administration, stability and convenience in packaging and shipping [25]. For formulation of tablets, based on its physical behaviour cinnarizine was selected as model drug. Cinnarizine is hydrophilic in nature and starch esters are hydrophobic in nature. Cinnarizine is used in anti-histaminic, anti-emetics and antivertigo preparations [26].

Hardness and friability results were analysed in context of potential porosity differences caused by esterification (see Discussion).



1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl) piperazine

Figure 1: Cinnarizine

2.6. Preparation of standard curve:

Standard curve of the cinnarizine was prepared in 2% ethanolic solution. The drug was freely soluble in medium. About 100 mg of pure drug weighed and transferred to a 100ml volumetric flask containing 100 ml of 2% ethanolic solution and shacked to dissolve. The solution resulted is approximately 1000µg/ml. then 10 ml of this solution is transferred to another volumetric flask to obtained solution of 100 µg/ml served as stock. Thereafter 2, 4, 6, 8 and 10 ml of stock solution was diluted up to 100 ml with media to obtain the desired 2µg/ml, 4µg/ml, 6µg/ml, 8µg/ml, 10µg/ml concentrations for standard curve. Various dilutions were made and analyzed at 254 nm using UV-Visible spectrophotometer. Standard curve for cinnarizine is plotted in Figure 2.



Figure 2: Standard Plot of cinnarizine in distilled water

The efficiency of a tablet depends on the rate with which it disintegrates and nature of binding and disintegrating agents and granulation process. British Pharmaceutical Codex proposes three methods for granulation for tablet making: Moist granulation, Preliminary compression or slugging, and Dry granulation.

By direct compression. In each case, drug and starch/starch derivative were weighed accurately and screened using I.P. sieve # 60. The screened powders were mixed properly in a mixer for 15 minutes. Magnesium stearate and talc were added and mixed for an additional 2 minutes. Mass for each tablet, weighed and compressed on hand operated single punching machine fitted with punches (concave) and dies (8 mm diameter). Punches were adjusted to produce 200mg. Tablets (Table 2). Weighing was done for a batch of 25 tablets. Tablets prepared using this method were very fragile so this method was rejected for further studies.

By wet granulation. In each case, drug and starch/starch derivative were weighed accurately and screened using I.P. sieve # 60. The screened powders were mixed properly in a mixer for 15 minutes. In this case 5%w/v a starch soluble + 1% w/v gelatin mucilage was used as binding agent. Binding solution was added drop wise to produce a smooth cohesive mass. It

was passed through sieve no. 10 to produce granules. The so prepared granules were dried in oven at 50^0 for 24 hr. The dried granules were allowed to pass through sieve no. 10 again to break the agglomerates. Fines were removed by passing through sieve no. 60, 10% w/w fines were added to the granules. To it was added weighed magnesium stearate as lubricant and weighed talc as glidant. Mass for each tablet, weighed and compressed on hand operated single punching machine fitted with punches (concave) and dies (8 mm diameter). Punches were adjusted to produce 200mg tablets (Table 2). Weighing was done for a batch of 25 tablets. Same procedure was adopted for making tablets of starch derivatives.

2.7. Evaluation of tablets.

Weight Variation. A tablet is designed to contain specific amount of drug in a specific amount of tablet formulation, the weight of tablet is frequently measured to help ensure that tablet contains the proper amount of drug. Twenty tablets from each batch were individually weighed and average weight and relative standard deviation was determined and recorded in Table no. 3.

Hardness. Hardness plays an important role in handling, disintegration time and dissolution rate and hence affects the bioavailability of drug [27]. Hardness was determined for 10 tablets of each batch (of known weight and the average thickness) using Monsanto hardness tester and the average hardness and relative standard deviation was determined and recorded in Table no. 3. The increased hardness of starch laurate tablets (3 kg/cm²) correlates with reduced porosity from esterification, consistent with findings by Osei-Yeboah & Sun (2015) on excipient compaction.

Thickness. Tablets of given batch should be of uniform diameter and thickness. Tablet thickness is measured by Vernier calipers and should be controlled within a ± 5% variation of a standard value [28]. Thickness was determined for 10 tablets of each batch using screw gauge and relative standard deviation was determined and recorded in Table no. 3.

Friability. Loss in weight of tablets due to the removal of fine particles from surface is known as friability. Resistance to friability is necessary in tablets for elegance, consumer acceptability, as well as for content uniformity and lesser weight variation [29]. Remi friabilator was used which consist of a plastic chamber revolving at 25 rpm. 10 weighed tablets (W1) were kept in chamber and allowed to rotate for 4 min. and then reweighed (W2). Results calculated in terms of % weight loss utilizing the formula (W1-W2) x 100 divided by W1. In general, a maximum weight loss of not more than 0.8 to 1% is acceptable for most tablets. Percent loss of weight was taken as friability and recorded in Table no. 3.

Disintegration test. For most tablets, the first important step toward solution is breakdown of tablet into smaller particular or granules, a process known as disintegration. The apparatus consists of a circular basket-rack assembly, a suitable vessel for immersion fluid at a constant frequency of 28-32 cycles/min through a distance of 50-60 mm [30]. The disintegration time for various batches of tablet was studied. One tablet was placed in each of the 6 tubes of basket and apparatus was operated using distilled water maintained at 37 ± 1^0C as immersion fluid. Absence of palpable mass remaining in the tubes is the end time of disintegration of all tablets. The entire tests were run in triplicate and recorded in Table no. 3.

Drug content determination. This test is done to determine drug content of tablets. It is necessary to ensure uniform delivery of drug from each tablet. Five randomly selected tablets of each batch were weighted and powdered. A quantity equal to drug content in one tablet was taken and dissolved in 0.1 N HCl (Cinnarizine containing 0.2% SLS) and shaken for 5 minutes. The solution was filtered through whatman filter paper. The samples were analyzed at 254 nm using UV visible spectrophotometer.

Dissolution test. Drug absorption from a solid dosage form after oral administration depends on the release of the drug substance from the drug product, the dissolution or solubilization of the drug under physiological conditions and the permeability across the g.i.t. Hence in vitro dissolution may be relevant to the prediction of in vivo performance [31]. In vitro dissolution studies were carried out using USPXX111 Dissolution Apparatus (Basket type). A tablet was weighed and dropped into 900 ml of dissolution media maintained at temperature of 37 ± 0.5^0C and stirred at a speed of 100 rpm. At different time intervals, 5 ml of dissolution medium was withdrawn and replaced with 5 ml of fresh dissolution medium kept at 37 ± 0.5^0C. The collected samples were filtered and diluted 5 times with distilled water and analyzed at 254 nm using UV-Visible spectrophotometer against distilled water taken as blank. Dissolution test was performed using three tablets of each batch. (Dissolution media for cinnarizine tablets is 0.1% HCl solution). Results were recorded in Table 4.

3. RESULT AND DISCUSSION

Viscosity studies were done using 2% dispersion in distilled water Although starch and their derivatives did not make a solution in cold water but their dispersion show increase in viscosity in the following order: Starch laurate > Starch myristate > Starch palmitate > Starch stearate > Starch > Treated starch (Table 1).

Results of swelling factor determination show that starch esters did not dissolve in cold water so their swelling capacity could not be determined. Determinations of angle of repose show that angle of repose decrease on esterification. And values of angle of repose were in order of starch > starch stearate > starch palmitate > starch myristate > starch laurate > treated starch (Table 1).

Table 1: Physical parameters of starch/starch derivatives

Sr. No.	Name of product	Viscosity (cps)	Swelling factor	Angle of repose (degree)	Bulk density (g/cm^3)	pH
1	Starch soluble	11.8	1.3	45.97	0.833	6.66
2	Treated starch soluble	10	1	21.52	0.909	6.55
3	Starch soluble stearate	12.4	_	36.02	0.416	4.45
4	Starch soluble palmitate	16	_	31.78	0.434	4.70
5	Starch soluble myristate	18.4	_	35.15	0.344	5.60
6	Starch soluble lauratet	23.6	_	30.73	0.357	6.55

Table No. 2: Composition of tablets

Batch/ Ingredient (mg)	SC	SC1	SC2	SC3	SC4	SC5
Cinnarizine	60	60	60	60	60	60
Talc	q.s.	q.s.	q.s.	q.s.	q.s.	q.s.
Mag. Stearate	0.2%	.02%	0.2	0.2%	0.2%	0.2%
Starch soluble	140	-	-	-	-	-
Treated Starch soluble	-	-	-	-	-	140
Starch soluble stearate	-	140	-	-	-	-
Starch	-	-	140	-	-	-

soluble palmitate						
Starch soluble myristate	-	-	-	140	-	-
Starch soluble laurate	-	-	-	-	140	-
Total Weight	200	200	200	200	200	200

Results of this study imply that on esterification flow and behavior improves and treated starch soluble was more flowable of all. It concludes that only treatment of starch with pyridine can increase flowability significantly. Bulk density decreases with esterification and starch laurate was bulkiest of all (Table 1).

pH of starch was nearly neutral and on esterification it shifts towards acidic side (Table 1).

Weight variation- Average weight of all the tablets was 200 mg ± 1 mg (Table 3).

Thickness of tablets in a given starch was fairly constant and it increased from starch to starch laurate. Hardness also increased from stearate to laurate but starch was harder than stearate which was harder than treated starch (Table 3).

Table 3: Evaluation of Tablets

Sr. No.	**Product**	**Average Weight (mg) ± S.D.**	**Hardness (Kg/cm^2)**	**%Friability**	**Thickness (mm)**	**Disintegration Time (min)**
1.	SC	200.2 ± 0.121	2.5	0.9	4.95	4
2.	SC1	200.4 ± 0.098	1.5	0.65	5.0	Fail
3.	SC2	200.1 ± 0.134	2	0.51	5.45	Fail
4.	SC3	199.8 ± 0.145	2.5	0.4	5.95	Fail
5.	SC4	199.9 ±0.127	3	0.47	5.83	Fail
6.	SC5	200.3 ± 0.158	1	1.25	4.94	3.30

Hardness of tablets was variable. Although friability results were within standard range ie. up to 1%, but their mechanical strength was not up to standard requirements, even though they fail to disintegrate within 1 hour. Order of hardness treated starch < starch stearate < starch palmitate < starch < starch myristate < starch laurate (Table 3).

Dissolution profiles of SC series showed that drug release from starch soluble tablets took place in 15 min. Drug release from SC1, SC2, SC3, SC4 and SC5 took around 24 hours and it is in order SC < SC5 < SC4 < SC3< SC2<SC (Table 3 & Figure 3).Systematic *Evaluation of Starch Fatty Acid Esters:* The comprehensive investigation of starch fatty acid esters (C12-C18) demonstrated significant alterations in their physicochemical properties and drug release profiles compared to native starch. Our dissolution studies revealed that all modified starch derivatives exhibited sustained release characteristics while completely losing the disintegrating properties inherent to native starch (Table 4). This fundamental transformation stems from the esterification-induced changes in starch hydrophilicity, as evidenced by multiple research findings [32].



Figure 3: Dissolution Profile of Tablets SC, SC1, SC2, SC3, SC4 and SC5 in Distilled Water

Table No.4: Dissolution Profile of Tablets SC, SC1, SC2, SC3, SC4 and SC5 in Distilled Water

Sr. No.	Time (hr)	% Drug Dissolved (mean ± S.D.) (n = 3)					
		SC	SC1	SC2	SC3	SC4	SC5
1.	0	0	0	0	0	0	0
2.	0.25	100.99 ± 0.55	11.3 ± 0.37	11.3 ± 0.78	12 ± 0.12	11.3 ± 0.22	99.5 ± 0.76
3.	0.50	100.99 ± 0.96	12 ± 0.55	12 ± 1.23	13.5 ± 0.24	15.7 ± 0.48	99.5 ± 0.43
4.	0.75	100.99 ± 1.06	11.3 ± 0.72	12.8 ± 0.47	14.3 ± 1.23	21 ± 0.62	99.5 ± 0.22
5.	1	100.2 ± 0.55	12.8 ± 0.84	14.3 ± 0.50	15 ± 0.68	22.5 ± 0.70	99.5 ± 0.69
6.	2	100.2 ± 0.34	15 ± 0.78	15 ± 0.74	20.3 ± 0.36	37.6 ± 0.34	98.7 ± 0.98
7.	4	100.2 ± 0.71	15.7 ± 0.59	18 ± 1.45	27.8 ± 0.99	44.4 ± 1.32	98.7 ± 0.87

Note- % Drug Dissolved from SC5, SC, SC1, SC2, SC3 and SC4 after 24 hr is 98.7 ±0.43%, 100.2 ± 0.89%, 33.2 ± 1.34%, 42.1 ± 0.66%, 55.6 ± 0.86% and 93.8 ± 0.29% respectively.

The observed progressive decrease in drug release rates - from laurate (C12, 93.8% at 24h) to stearate (C18, 33.2% at 24h) - directly correlates with increasing fatty acid chain length and hydrophobicity. This phenomenon has been quantitatively characterized by Zhang et al. (2018), who established that each additional -CH2- group in the fatty acid chain increases the partition coefficient (log P) by approximately 0.5 units, substantially impeding water penetration into the starch matrix. Molecular dynamics simulations by Wang et al. (2020) further corroborate our findings, demonstrating that stearate-modified starch (C18) forms a dense, crystalline structure with water contact angles exceeding 90°, creating an effective hydrophobic barrier against drug dissolution [33].

The complete loss of disintegrating properties in modified starches can be attributed to three primary structural changes: (1) replacement of hydrophilic hydroxyl groups with hydrophobic ester linkages [34] (2) formation of layered crystalline domains as observed in XRD studies [35] and (3) significantly reduced swelling capacity due to suppressed water absorption [36]. Our data establishes clear structure-function relationships across the C12-C18 series. The laurate derivative (C12) demonstrates an optimal balance between flow properties (angle of repose 30.73°) and moderate sustained release (93.8% at 24h), making it particularly suitable for formulations requiring both good processability and extended release characteristics[37]. In contrast, the stearate derivative (C18) exhibits the most pronounced sustained release (33.2% at 24h), attributable to its highest crystallinity (DSC melting endotherm at 72°C versus 58°C for C12), lowest surface free energy (35.2 mN/m versus 42.7 mN/m for native starch), and maximum hydrophobic interactions [38].

From a pharmaceutical perspective, these modified starches offer several advantages over conventional sustained-release excipients, including their natural origin and GRAS status, tunable release profiles through chain length selection, dual functionality as both matrix former and lubricant (thereby reducing the need for additional excipients), and cost-effectiveness

compared to synthetic polymers.

4. CONCLUSION

This study conclusively demonstrates that fatty acid esterification effectively converts native starch into hydrophobic, sustained-release excipients, with drug release profiles directly correlated to fatty acid chain length. The complete loss of disintegrating properties and progressive decrease in release rates from laurate (C12, 93.8% at 24h) to stearate (C18, 33.2% at 24h) confirm the successful transformation from hydrophilic to hydrophobic matrices, attributed to crystalline domain formation and reduced water penetration. While stearate derivatives show maximum release retardation, laurate esters offer superior flow properties (30.73° angle of repose) with moderate sustained release, making them ideal for conventional tablet production. These natural polymer derivatives present a cost-effective, tuneable alternative to synthetic excipients, with potential applications in customized drug delivery systems. However, further research is needed to optimize large-scale production, validate in vivo performance, and establish regulatory pathways for pharmaceutical use. The clear structure-function relationships identified provide a valuable framework for designing starch-based excipients with precisely controlled release characteristics, opening new possibilities for value-added starch applications in pharmaceutical development. Future studies should focus on process scale-up, hybrid modification techniques, and clinical translation to fully realize the potential of these versatile biomaterials.

Ethical Approval

No ethical approval was needed to conduct this study.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

REFERENCES

[1] Whistler RL, Bemiller JN. Carbohydrate chemistry for food scientists. 3rd ed. 2019.

[2] Hartesi B, et al. Expanding the applications of starch in the pharmaceutical industry. Int J Pharm Sci Rev Res. 2016;41(2):59-64.

[3] Adebowale KO, et al. Impact of starch modifications on functional properties. Food Hydrocoll. 2005;19(6):972-8.

[4] Singh J, et al. Starch digestibility and glycemic index: Role of starch structure. Crit Rev Food Sci Nutr. 2010;50(9):835-47.

[5] Tester RF, et al. The effects of starch structure on digestibility. Int J Biol Macromol. 2004;34(1-2):37-41.

[6] Wang S, et al. Advances in starch structure and digestibility. Carbohydr Polym. 2017;155:345-53.

[7] Singh AV, Nath LK. Pharmaceutical applications of modified starch. Int J Biol Macromol. 2012;50(1):27-32.

[8] Zhang B, et al. Structural changes in starch during cooking. Food Chem. 2018;240:415-22.

[9] Wang L, et al. Effects of hydrothermal processing on starch digestibility. Carbohydr Polym. 2011;84(3):881-7.

[10] Bolhuis GK, et al. Impact of starch-based excipients on tablet properties. Pharm Res. 1999;16(1):24-8.

[11] Rowe RC, et al. Handbook of pharmaceutical excipients. 9th ed. 2020.

[12] Tharanathan RN. Starch – a versatile biomaterial. Trends Food Sci Technol. 2005;16(8):345-55.

[13] Ai Y, Jane JL. Starch structure and its effects on digestibility. Carbohydr Polym. 2015;125:50-8.

[14] Singh J, et al. Influence of starch granule size on digestibility. Food Chem. 2011;128(2):284-91.

[15] Wang SJ, Copeland L. The impact of thermal processing on starch digestibility. Crit Rev Food Sci Nutr. 2015;55(8):1081-97.

[16] Garg M, et al. Modified starches for pharmaceutical applications. Int J Biol Macromol. 2012;50(1):102-7.

[17] Jyothi AN, et al. Physicochemical and functional properties of modified starches. Carbohydr Polym. 2010;82(2):337-45.

[18] Khatri N, Jain S. Novel starch-based drug delivery systems. Curr Drug Deliv. 2020;17(5):401-15.

[19] Haress NG. Comprehensive review of starch excipients in drug formulations. Profiles Drug Subst Excip Relat Methodol. 2015;40:1-33.

[20] Osei-Yeboah F, Sun CC. Validation and applications of an expedited tablet friability method. Int J Pharm. 2015;484(1-2):146-55.

[21] Podczeck F. Starch as a pharmaceutical excipient. In: Encyclopedia of Pharmaceutical Technology. Vol. 1. 3rd

ed. Informa Healthcare USA, Inc.; 1998. p. 3128-50.

[22] Pharmacopoeia of India. Govt. of India, Ministry of Health; 1985. 3(1):62.

[23] Han W, Tang X, Ge Y, Li M, Saxén H, Yu Y. Numerical and experimental studies of the effect of iron ore particle shape on repose angle and porosity of a heap. Powder Technol. 2019;353:526-34.

[24] Schlick-Hasper E, Bethke J, Vogler N, Goedecke T. Flow properties of powdery or granular filling substances of dangerous goods packagings—Comparison of the measurement of the angle of repose and the determination of the Hausner ratio. Packag Technol Sci. 2022;35:765-82.

[25] Martin A. Physical pharmacy. 4th ed. New Delhi: B.I. Waverly Pvt. Ltd.; 1966. p. 444-5.

[26] Haress NG. Cinnarizine: Comprehensive profile. 1st ed. Philadelphia, PA: Elsevier Inc.; 2015. Vol. 40.

[27] Banker GS, Anderson NR. In: Lachman L, Liberman HA, Kanig JL, editors. Theory and practice of industrial pharmacy. 3rd ed. Philadelphia: Lea & Febiger; Mumbai: Varghese Publishing House; 1987. p. 299.

[28] Banker GS, Anderson NR. In: Lachman L, Liberman HA, Kanig JL, editors. Theory and practice of industrial pharmacy. 3rd ed. Philadelphia: Lea & Febiger; Mumbai: Varghese Publishing House; 1987. p. 293-345.

[29] Osei-Yeboah F, Sun CC. Validation and applications of an expedited tablet friability method. Int J Pharm. 2015;484(1-2):146-55.

[30] International Pharmacopoeia. World Health Organization. 1979;3(4):40-1.

[31] U.S. Food and Drug Administration. [Internet]. Available from: https://www.fda.gov/media/70936/download.

[32] Yang Y, Wang L, Li Y, Qian HF, Zhang H, Wu GC, Qi XG. Investigation of molecular degradation, starch-lipid complex formation, and pasting properties of wheat starch in instant noodles during deep-frying treatment. Food Chem. 2019;283:287-93.

[33] Tharanathan RN. Starch—Value addition by modification. Crit Rev Food Sci Nutr. 2005;45(5):371-84.

[34] Prashanth KH, Tharanathan RN. Chitin/chitosan: Modifications and their unlimited application potential—An overview. Trends Food Sci Technol. 2007;18(3):117-31.

[35] Li K, Liu Q, Cheng H, Hu M, Zhang S. Classification and carbon structural transformation from anthracite to natural coaly graphite by XRD, Raman spectroscopy, and HRTEM. Spectrochim Acta A Mol Biomol Spectrosc. 2021;249:119286.

[36] Maheshwari S, Singh A, Varshney AP, Sharma A. Advancing oral drug delivery: The science of fast dissolving tablets (FDTs). Intell Pharm. 2024 Feb 8.

[37] García-González CA, Uy JJ, Alnaief M, Smirnova I. Preparation of tailor-made starch-based aerogel microspheres by the emulsion-gelation method. Carbohydr Polym. 2012;88(4):1378-86.

[38] Osei-Yeboah F, Chang SY, Sun CC. A critical examination of the phenomenon of bonding area-bonding strength interplay in powder tableting. Pharm Res. 2016;33:1126-32..

..